Jack, sorry to be so late but it's been a busy day, thanks in part to Shero's weekend ruminations. More on that later.
My most reliable marketmaker tells me today's trading was mostly one total order of 40,000 shares and it was completed, I don't know how many trades it required. Since at least some of the mm's probably knew of the order the public did the buying so this, in retrospect, was a strong day for us. More buyers than sellers but one of the sellers was a big 'un. For you chartists, I am told, Techniclone is building a powerful pennant formation. The timing seems right.
Shero, it's true that the same active receptor (a histone) is in all necrotic tumors but it may not work as well in different cancers, or so the reasoning goes. We know it works especially well in glioma, for instance, and all it had to do to show efficacy was penetrate the impassable blood brain barrier. Ha! I'm on your side, of course, but we have a system here that is also finally going to be on your side. Like the bumper sticker said, "I may be slow but I'm ahead of you.' Let's take advantage of the system.
I think I can illustrate my point better; Idec and Coulter both use the CD20 marker in the b cell line for low grade NHL. It may be the dominant marker in LG but is not as prevalent in intermediate/high grade where Lym-1's HLA marker is dominant, at least between these ab's. BTW, Genzymes' announcement today is really going to put the pressure on the low graders (go to GENZ on SI, sorry i forgot to copy it). I think that Genzyme's idiotypic cancer vaccine coupled with TCLN's Lym-2 (labled with any fusion protein/cytokine) will be the treatment of choice for lg NHL eventually. This time when IDPH/CLTR revert to form and start claiming (again) that they can treat intermediate/high grade as well as TCLN I don't expect the new CEO to roll over.
Shero, your venting cost me a lot of phone time the last 24 hours but it was like a refresher course so thanks. I have talked to millions and millions of shares worth of influence at TCLN and no one considers your conjecture a possibility. Count the votes. Compensation shouldn't even be much of an issue. Lon Stone's argument in favor of all the stock options granted heretofore has always been that they are performance dependent. So what's changed? Time to expiration and no more loans (Up with the proletariat, I mean shareholders!). I think the management/employees are more interested in stock performance than ever before. So unless a known securities violator or something is nominated I would say we got us a new CEO soon, and unanimously. With this pipeline the options granted to this guy will make him wealthy and as well known as a Gozuita, Iacocca, or Eisner in a decade or so. We're getting someone who has paid his dues and can handle the duty. There's no one like that now. Rarely has there been such a great opportunity for someone to increase his net worth and correspondingly increase so many others at the same time.
BTW Shero, was your source the same one who said that Bix and Rudy would never resign from the board or that TCLN would never reacquire Lym-1? Never mind, it's water under the bridge soon enough. Relax, good buddy, whoever you are. |
